bioAffinity Technologies Announces Award Of Therapeutic Patent For Treatment Of Cancer; Indian Patent Office Grants Patent Related To Porphyrin Compounds For Targeted Cancer Treatment
Portfolio Pulse from Benzinga Newsdesk
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW) announced that its subsidiary OncoSelect Therapeutics, LLC was granted an Indian patent for cancer treatment using porphyrin compounds. This patent is a significant addition to bioAffinity's portfolio, which includes 16 awarded patents and 23 pending applications. The company's first product, CyPath® Lung, is a noninvasive diagnostic test for early-stage lung cancer using porphyrin-based technology.
January 23, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
bioAffinity Technologies has been granted an Indian patent for its porphyrin-based cancer treatment, which could enhance the company's intellectual property and potentially lead to future revenue streams.
The grant of a new patent typically strengthens a company's intellectual property portfolio, which can be critical for biotech companies like bioAffinity Technologies. This could lead to increased investor confidence and potential partnerships or licensing deals in the future, especially in the Indian market. The news is directly related to BIAF and is likely to be seen positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100